title: Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22).
abstract: Tumour lysis syndrome (TLS) is caused by rapid breakdown of malignant cells resulting in electrolyte disturbances and acute renal failure. TLS has rarely been described in patients with acute myelogenous leukaemia (AML). Between November 1997 and July 2001, 114 consecutive adult AML patients aged <60 yr received induction chemotherapy consisting of cytosine arabinoside 1.5 g m(-2) q 12 h x 12 doses and daunorubicin 45 mg m(-2) d(-1) x 3 doses. During induction chemotherapy (CT), seven patients (6.1%, 95% CI 2.5-12.2) developed fulminant TLS, resulting in acute renal failure; five of these seven patients had inversion of chromosome 16 [inv(16)(p13;q22)], and one patient had a biological equivalent [t(16,16)(p13;q22)]. Four of the TLS patients underwent leukapheresis for a presenting white blood cell (WBC) count > 100 x 10(9) L(-1) prior to commencing chemotherapy, and six patients subsequently required haemodialysis for a median of 2 (range 1-8) wk. One TLS patient died of intracerebral hemorrhage on day 10 and another patient of multiorgan failure on day 17. Of the other five patients, all entered a complete remission (CR) and recovered normal renal function. Four patients remain in continuous CR [median follow-up 20 (range 12-25) months]. One patient relapsed at 12 months and again developed TLS on re-induction. In univariate analysis, TLS patients were more likely to have an elevated presentation and pre-chemotherapy WBC counts, elevated serum creatinine, and uric acid levels at presentation, as well as an inv(16). In multivariate analysis, only serum creatinine and inv(16) remained statistically significant (P < 0.001 for each). Patients with an inv(16) are a unique AML subgroup at high risk for fulminant TLS.
authors.affiliation: Leukemia and Bone Marrow Transplantation Program of British Columbia: Division of Hematology, Vancouver General Hospital, JPP3, 950 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E3. mseftel@bccancer.bc.ca
authors.forename: M D
authors.initials: MD
authors.lastname: Seftel
authors.forename: H
authors.initials: H
authors.lastname: Bruyere
authors.forename: M
authors.initials: M
authors.lastname: Copland
authors.forename: D E
authors.initials: DE
authors.lastname: Hogge
authors.forename: D E
authors.initials: DE
authors.lastname: Horsman
authors.forename: S H
authors.initials: SH
authors.lastname: Nantel
authors.forename: J D
authors.initials: JD
authors.lastname: Shepherd
authors.forename: J C
authors.initials: JC
authors.lastname: Lavoie
authors.forename: A
authors.initials: A
authors.lastname: Le
authors.forename: H J
authors.initials: HJ
authors.lastname: Sutherland
authors.forename: C L
authors.initials: CL
authors.lastname: Toze
authors.forename: T J
authors.initials: TJ
authors.lastname: Nevill
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D007446:Chromosome Inversion; D002885:Chromosomes, Human, Pair 16; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015275:Tumor Lysis Syndrome / Q000209:etiology* / Q000401:mortality / Q000503:physiopathology
chemical_list: D000970:Antineoplastic Agents; D003561:Cytarabine; D003630:Daunorubicin